Jonathan's practice involves providing commercially-focussed advice on patent origination, patent strategy and portfolio management, licensing and due diligence, prosecuting and defending European patent oppositions, and conducting patent litigation in the UK and Europe.
His practice draws in this variety of experience and extends to a wide range of chemical and pharmaceutical subject matter. Jonathan's practice in the pharmaceutical area has covered both contentious and non-contentious issues and he has provided external consultancy services to a number of large pharmaceutical companies over the last 20 years.
His practice involves providing commercially focused advice to C-suite business leaders, R&D groups, and public institutions on all aspects of patent strategy and portfolio management. This includes obtaining and defending patent rights, providing opinions on freedom to operate where third party intellectual property rights exist, conducting due diligence to support corporate acquisition and licensing deals, challenging third party patent rights and pan-European pharmaceutical litigation.
Jonathan has worked on a number of high profile pharmaceutical matters including working as part of the patent procurement team for Viagra™; prosecution and litigation surrounding Augmentin™, Ritalin™ and Fosrenol™; opposition/appeal work on Zithromax™, Perindopril and Sovaldi™ and due diligence work to support acquisitions (eg New River Pharmaceuticals and Renovo, and IPO's (eg Redx and NuCana plc), and private equity investment funding (eg OriBiotech).
In the non-pharmaceutical area, he has been responsible for filing all of the foundation patents for graphene on behalf of Manchester University's two Nobel Prize winners Geim and Novoselov.
Jonathan's clients include large and small companies, universities and government organisations.
Cert in IP Law Queen Mary, London
C. Chem, FRSC
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.